



EXPRESS MAIL LABEL #EL 422247885 US

6-20-05

JC04 Rec'd PCT/PTO 17 JUN 2005

PCT  
#4

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Matthew BAKER *et al.* )  
Application No. 10/517,707 )  
Filed: December 10, 2004 ) Group Art Unit: Unknown  
For: MODIFIED BRYODIN 1 WITH ) Attorney Docket No. MER-134  
REDUCED IMMUNOGENICITY )

RESPONSE TO NOTIFICATION  
TO COMPLY WITH SEQUENCE REQUIREMENTS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


This paper is in response to the Notification To Comply With Requirements For Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, mailed May 18, 2005 for the above-identified application.

Please amend the application to enter the Substitute Sequence Listing submitted herewith in paper copy and Computer Readable Form.

SEQ ID NO: 7 in the Sequence Listing has been corrected to delete the erroneous inclusion of Xaa at position 1 in the sequence. The positions for the correct Xaa amino acids in SEQ ID NO: 7 have been adjusted accordingly. Support for the amendment is found in the specification at page 11, where the initial X<sup>0</sup> in SEQ ID NO: 7 is indicated to be a hydrogen or targeting moiety, not an amino acid. No new matter is added by this amendment.

Respectfully submitted,

Dated: 17 June 2005

By:   
Talivaldis Cepuritis (Reg. No. 20,818)

OLSON & HIERL, LTD.  
20 North Wacker Drive  
36th Floor  
Chicago, Illinois 60606  
(312) 580-1180



Rec'd PCT/PTO 17 JUN 2005

HY

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Matthew BAKER *et al.* )  
Application No. 10/517,707 )  
Filed: December 10, 2004 ) Group Art Unit: Unknown  
For: MODIFIED BRYODIN 1 WITH ) Attorney Docket No. MER-134  
REDUCED IMMUNOGENICITY )

TRANSMITTAL OF SUBSTITUTE SEQUENCE LISTING  
AND STATEMENT UNDER 37 CFR §1.824

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

A paper copy of a Substitute Sequence Listing for the above-identified application is being transmitted herewith, along with a Computer Readable Form (CRF) on a 3.5 inch diskette in accordance with 37 CFR §1.824. I hereby state, to the best of my information and belief, that the sequence listing information in Computer Readable Form is identical to the paper copy of the Substitute Sequence Listing. No new matter is added by this Substitute Sequence Listing.

Respectfully submitted,

Dated: 17 June 2005

By:

  
Talivaldis Cepuritis (Reg No. 20,818)

OLSON & HIERL, LTD.  
20 North Wacker Drive  
36th Floor  
Chicago, Illinois 60606  
(312) 580-1180